Vivek Subbiah: Distinct clinical outcomes and biological features of specific KRAS mutants in pancreatic cancer

Vivek Subbiah shared a post on X:

“Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer – Cancer Cell.
KRASG12R tumors are associated with decreased distant recurrence and improved survival as compared to KRASG12D.”

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

Authors: Caitlin A. McIntyre, Adrien Grimont, Jiwoon Park, Yinuo Meng, Whitney J. Sisso, Kenneth Seier,  Gun Ho Jang, Henry Walch, Victoria G. Aveson, David J. Falvo, William B. Fall, Christopher W. Chan, Andrew Wenger, Brett L. Ecker, Alessandra Pulvirenti, Rebecca Gelfer, Maria Paz Zafra, Nikolaus Schultz. Wungki Park, Eileen M. O’Reilly, Shauna L. Houlihan, Alicia Alonso, Erika Hissong, George M. Church, Christopher E. Mason, Despina Siolas, Faiyaz Notta, Mithat Gonen, Lukas E. Dow, William R. Jarnagin and Rohit Chandwani

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.